Clinical Trial Finds Kratom Well-Tolerated With Low Abuse Potential at Tested Doses

Why it matters

This is one of the most rigorous placebo-controlled clinical trials to date examining kratom's abuse potential in humans, providing direct clinical evidence to inform ongoing FDA and DEA regulatory decisions about kratom's legal status.

The big picture

As kratom use in the U.S. grows — with millions consuming it for pain, energy, and mood management — regulatory agencies have faced pressure to classify it as a Schedule I substance. Prior assessments relied heavily on animal data and case reports. This randomized, double-blind, placebo-controlled study following FDA-recommended protocols fills a major evidence gap with real human clinical data. The study was conducted by Pinney Associates and Thomas Jefferson University researchers.

Key findings

• 116 healthy kratom-naive adults received 500–4,000mg dried kratom leaf (6.65–53.2mg mitragynine) or placebo across single and multiple daily doses in a randomized controlled design
• Subjective drug effects were dose-related but modest, with statistically significant increases over placebo only at the highest single dose tested
• Drug Effects Questionnaire responses decreased following repeated dosing over 15 consecutive days — suggesting habituation rather than escalation
• No participants met clinical thresholds for meaningful opioid withdrawal on validated scales (COWS or SOWS)
• No serious adverse events or deaths were reported; abuse-related adverse events were mild and resolved without treatment

What they say

"Oral administration of kratom at tested doses was well tolerated and associated with modest, dose-related subjective effects, minimal withdrawal symptoms, and low ARTEAE rates. Findings support further research on kratom's safety and therapeutic potential, while emphasizing the importance of dose control and product standardization." — Coe et al., Drug Testing and Analysis, 2026

Bottom line

**In the most rigorous human clinical trial to date, kratom produced modest dose-related effects, minimal withdrawal, and no serious adverse events — strengthening the case that it has lower abuse potential than conventional opioids.**